BMY241108C60000
- 0.01
- -0.01-50.00%
Bristol-Myers Squibb Newsroom
Analysts' Top Healthcare Picks: Bristol-Myers Squibb (BMY), Agios Pharma (AGIO)
Bristol-Myers Squibb: Hold Rating Maintained Amid Positive Clinical Trials and Long-term EPS Concerns
Leerink Partners Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $55
A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $36 to $60
Bristol-Myers Squibb Is Maintained at Market Perform by BMO Capital
Bristol-Myers Squibb Analyst Ratings
A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $36 to $60
Morgan Stanley Trims Price Target on Bristol-Myers Squibb to $36 From $37, Keeps Underweight Rating
Bristol-Myers Squibb Analyst Ratings
Citi Downgrades Bristol-Myers Squibb(BMY.US) to Hold Rating, Cuts Target Price to $55
Leerink Partners Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Announces Target Price $53
Bristol-Myers Squibb: Navigating Financial Adjustments and Competitive Pressures Amidst a Hold Rating
Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $60 From $57
Bristol-Myers Squibb Analyst Ratings
Bristol-Myers Squibb: Hold Rating With Anticipated Revenue Outperformance Offset by Generic Competition Concerns
Morgan Stanley Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Maintains Target Price $37
UBS Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $54
TD Cowen Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $59
Barclays Maintains Underweight on Bristol-Myers Squibb, Raises Price Target to $43
Bristol-Myers Squibb Is Maintained at Hold by TD Cowen